Freimer, Jacob W. http://orcid.org/0000-0001-9239-2272
Shaked, Oren
Naqvi, Sahin http://orcid.org/0000-0003-2635-7967
Sinnott-Armstrong, Nasa http://orcid.org/0000-0003-4490-0601
Kathiria, Arwa
Garrido, Christian M.
Chen, Amy F.
Cortez, Jessica T. http://orcid.org/0000-0002-6314-7267
Greenleaf, William J. http://orcid.org/0000-0003-1409-3095
Pritchard, Jonathan K. http://orcid.org/0000-0002-8828-5236
Marson, Alexander http://orcid.org/0000-0002-2734-5776
Article History
Received: 2 July 2021
Accepted: 26 May 2022
First Online: 11 July 2022
Competing interests
: A.M. is a compensated cofounder, member of the boards of directors and a member of the scientific advisory boards of Spotlight Therapeutics and Arsenal Biosciences. A.M. is a cofounder, member of the boards of directors and a member of the scientific advisory board of Survey Genomics. A.M. is a compensated member of the scientific advisory board of NewLimit. A.M. owns stock in Arsenal Biosciences, Spotlight Therapeutics, NewLimit, Survey Genomics, PACT Pharma and Merck. A.M. has received fees from 23andMe, PACT Pharma, Juno Therapeutics, Trizell, Vertex, Merck, Amgen, Genentech, AlphaSights, Rupert Case Management, Bernstein and ALDA. A.M. is an investor in and informal advisor to Offline Ventures and a client of EPIQ. The Marson laboratory has received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead and Anthem. W.J.G. is a consultant for 10x Genomics, which has licensed IP associated with ATAC-seq. W.J.G. has additional affiliations with Guardant Health (consultant) and Protillion Biosciences (cofounder and consultant). J.W.F. is a consultant for NewLimit. J.W.F., O.S., J.K.P. and A.M. are listed as inventors on a patent application related to this work. The remaining authors declare no competing interests.